Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Feb 04, 2024 10:56pm
148 Views
Post# 35862372

RE:A layman's thoughts on Roche and Adaptive Phase 3.

RE:A layman's thoughts on Roche and Adaptive Phase 3.I think idea for adaptive P3 came from PanCan.  They had ok from FDA to run such a program. 

Because Pancreatic Cancer is so brutal and spreads so fast I think they ok'd the idea of an adaptive type program with an ongoing running control arm because of the huge unmet need in Pancreatic cancer that is well on track to become the number two in cancer deaths worldwide.

I still think that Pancreatic Cancer is the ULTIMATE test to see if Pelareorep can go after metastatic cancers that spreads well beyond the Pancreas very quickly. 

After all 90% of people who die of Metastatic cancers don't die from the original cancer they die from one that has spread to another organ. So with current cancer therapies only 10% of people are going to survive a Metastatic cancer long-term.     







<< Previous
Bullboard Posts
Next >>